MedTrace Logo

Effect of Cenicriviroc on HIV Neurocognitive Impairment

NCT02128828 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-08-20

Study results available
· View outcomes & findings →

Summary

The study hypothesis is that cenicriviroc will improve cognition in HIV infected individuals with cognitive impairment. The investigators will study the effect of cenicriviroc on cognition in 24 subjects over a 24 week period.

Conditions

  • AIDS Dementia Complex
  • HIV-1-Associated Cognitive Motor Complex
  • Human Immunodeficiency Virus

Interventions

DRUG

cenicriviroc

cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc

Sponsors & Collaborators

  • Tobira Therapeutics, Inc.

    collaborator INDUSTRY

  • University of Hawaii

    lead OTHER

Principal Investigators

  • Cecilia Shikuma, MD · University of Hawaii - Hawaii Center for AIDS (HICFA)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02128828 on ClinicalTrials.gov